Notice of AGM and Annual Report & Accounts

RNS Number : 8386W

Sareum Holdings PLC

20 November 2017

 

(AIM: SAR)

20 November 2017

Sareum Holdings plc

("Sareum" or "the Company")

Notice of AGM and Annual Report & Accounts

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, has notified its shareholders that its Annual General Meeting ("AGM") will take place at 10.00 a.m. on 14 December 2017 at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5SY.

On 17 November 2017, the Company Annual Report and Accounts for the year ended 30 June 2017 was posted to shareholders who requested a hard copy and the notice convening the 2017 AGM was posted to all shareholders. A copy of both documents has been placed on the Company website.

For further information, please contact: 

Sareum Holdings plc
Tim Mitchell	01223 497 700
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / James Sinclair-Ford	020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce	020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David Dible	020 7282 9571

Notes for editors: 

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -

 

END

 

 

NOAUBUARBOAAAAA